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Background: Alterations in the redox balance are involved in the origin, promotion and progression of cancer.
Inter-individual differences in the oxidative stress regulation can explain a part of the variability in cancer susceptibility.
The aim of this study was to evaluate if polymorphisms in genes codifying for the different systems involved in
oxidative stress levels can have a role in susceptibility to breast cancer.
Methods: We have analyzed 76 single base polymorphisms located in 27 genes involved in oxidative stress regulation
by SNPlex technology. First, we have tested all the selected SNPs in 493 breast cancer patients and 683 controls and
we have replicated the significant results in a second independent set of samples (430 patients and 803 controls).
Gene-gene interactions were performed by the multifactor dimensionality reduction approach.
Results: Six polymorphisms rs1052133 (OGG1), rs406113 and rs974334 (GPX6), rs2284659 (SOD3), rs4135225 (TXN) and
rs207454 (XDH) were significant in the global analysis. The gene-gene interactions demonstrated a significant four-variant
interaction among rs406113 (GPX6), rs974334 (GPX6), rs105213 (OGG1) and rs2284659 (SOD3) (p-value = 0.0008) with
high-risk genotype combination showing increased risk for breast cancer (OR = 1.75 [95% CI; 1.26-2.44]).
Conclusions: The results of this study indicate that different genotypes in genes of the oxidant/antioxidant pathway
could affect the susceptibility to breast cancer. Furthermore, our study highlighted the importance of the analysis of the
epistatic interactions to define with more accuracy the influence of genetic variants in susceptibility to breast cancer.
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Despite breast cancer (BC) being the most frequent can-
cer in women in western countries and the second cause
of cancer death after lung cancer [1], the risk factors that
lead to the disease are not completely understood, al-
though is widely accepted that they include a combin-
ation of environmental and genetic factors. For genetic
approximation, a polygenic model has been proposed in
which a combination of common variants, having indi-
vidually a modest effect, together contribute to BC pre-
disposition [2].
Numerous evidence links carcinogenesis and oxidative
stress regulation, including prooxidant and antioxidant* Correspondence: pilar.eroles@uv.es
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unless otherwise stated.defense systems [3-7]. Oxidative stress is defined as an
imbalance in the production of reactive oxygen species
(ROS) and reactive nitrogen species (RNS) and their re-
moval by antioxidants. When this imbalance occurs, bio-
molecules are damaged by ROS and RNS and normal
cellular metabolism is impaired, leading to changes of
intra- and extracellular environmental conditions. ROS
can cause lesions in DNA, such as mutations, deletions,
gene amplification and rearrangements, that may lead to
malignant transformations and cancer initiation and pro-
gression [8-10]. The effect of ROS and RNS, however, is
balanced by the anti-oxidant action of non-enzymatic
and anti-oxidant enzymes maintaining cellular redox
levels under physiological conditions [4,11].
Previous studies with knockout animals that lack anti-
oxidant enzymes support the view that ROS contributeral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mice deficient in the antioxidant enzyme CuZnSOD
showed increased cell proliferation in the presence of
persistent oxidative damage contributing to hepatocarci-
nogenesis later in life [12]. Another study showed that
mice lacking the antioxidant enzyme Prdx1 had a short-
ened lifespan owing to the development, beginning at
about 9 months, of severe hemolytic anemia and several
malignant cancers [13].
In this context, single nucleotide polymorphisms (SNPs)
in components of the cellular redox systems can modify
the redox balance and take part in both the BC initiation
and/or progression, as well as determine possible thera-
peutic treatments [14-17].
Despite the importance of oxidative stress in the devel-
opment and progression of cancer, few studies have eval-
uated the relationship between genetic modification in
genes coding for enzymes relatives to the redox system
and the susceptibility to develop BC. The previous stud-
ies had focused mainly on the analysis of genes related
to antioxidant defense enzymes [18,19], but the informa-
tion about modifications in genes involved in the oxida-
tion process is relatively sparse.
The aim of this study was to evaluate the association
between common variants in genes coding for proteins
related to the redox system (antioxidant and oxidant sys-
tems or proteins) and the susceptibility to develop BC.
We hypothesized that common SNPs related to the
redox pathway are associated with an altered risk for
BC. We chose 76 SNPs on which to perform a two-step
study: one first exploratory set and a second, independ-
ent, validation set. We also decided to investigate the
impact of complex interactions between SNPs at differ-
ent genes of the stress oxidative pathway. To address
this issue, we analyzed the effects of gene-gene interac-
tions by the multifactor dimensionality reduction (MDR)
approach. This analysis was carried out in four SNPs
that were statistically significant in the combinatorial set.
Methods
Study population
The underlying analyses were carried out in a Caucasian
Spanish population. The study was carried out in two steps
with two population groups. A first group of 1176 samples
was composed of 493 female patients diagnosed for BC be-
tween the years 1998–2008 at La Paz Hospital and Founda-
tion Jimenez Díaz (Madrid), and 683 healthy women
controls recruited at the Hospital of Valladolid (Spain).
Thereupon, we chose the polymorphisms that showed
marginally significant association (p-value < = 0.15), and
we replicated the procedure in a second independent
group (n = 1233) where we included 430 female patients
diagnosed for BC between the years 1988–1998 at the
Clinic Hospital of Valencia (Spain) and 803 samplesfrom cancer-free women recruited at the blood donor
bank at the same Hospital. Blood was collected between
2010 and 2011 during periodical patient visits. The
blood from controls was extracted between the years
2009 and 2012. In both groups, the controls were
women without pathology or history of cancer. Controls
were not matched to cases, but were similar in age. In
group 1, cases’ mean age was 57.5 (range 23.5-89.5), and
that for donors was 52.7 (21.5-96.5). In group 2, cases’
mean age was 54.1 (20.5-86.5) while in donors, it was 54
(22.5-92.5).
We selected this staged approach because it allowed
us to analyze only those polymorphisms with indicative
results and reduced the number of genotyping reactions
without significantly affecting statistical power [18,20].
The research protocols were approved by the ethics
committee of the INCLIVA Biomedical Research Insti-
tute. All the participants in the study were informed and
gave their written consent to participate in the study.
Single nucleotide polymorphisms selection and
genotyping
Two public databases were used to collect information
about SNPs in oxidative pathway genes: NCBI (http://www.
ncbi.nlm.nih.gov/projects/SNP/) and HapMap (http://www.
hapmap.org). The selection of polymorphisms was per-
formed by SYSNP [20] and by a literature search in
PubMed, Scopus and EBSCO databases using the terms
“breast cancer and polymorphisms and oxidative”, along
with additional terms such as “SNPs and oxidative pathway
and susceptibility”, and their possible combinations. The
following criteria were used to select the SNPs: functional
known or potentially functional effect, location in promoter
regions, minor allele frequency (MAF) over 0.1 in
Caucasian populations analyzed previously, localization
and distribution along the gene (including upstream
and downstream regions) and low described linkage
disequilibrium between candidate polymorphisms. We
included variants with potential influence in the gene
and protein function, as well as the most important var-
iants described in the literature.
Finally, we select a total of 76 polymorphisms located in
27 genes related to the redox system: 17 were classified as
antioxidant genes (CAT, GCLC, GCLM, GNAS, GPX6,
GSR, GSS, M6PR, MSRB2, OGG1, SOD1, SOD2, SOD3,
TXN, TXN2, TXNRD1, TXNRD2) and 10 as reactive spe-
cies generators (mainly NADPH oxidase-related genes
CYBB, NCF2, NCF4, NOS1, NOS2A, NOX1, NOX3,
NOX4, NOX5 and XDH). Reference names and character-
istics of the selected SNPs are provided in Table 1.
Experimental procedures
The blood samples remained frozen until the DNA
extraction was performed. Genomic DNA was
Table 1 Summary of the 76 selected SNPs in 27 genes
Gene Chr SNP id Allelesa Chr position Location MAF controlsb HWE controlsc
CAT 11 rs1049982 C/T 34417117 5´UTR 0.355 0.66
rs475043 A/G 34450377 downstream 0.334 0.73
rs511895 A/G 34444305 intronic 0.332 0.73
rs7104301 A/G 34450214 downstream 0.308 0.18
rs769214 A/G 34416293 promoter 0.349 0.61
CYBB X rs5964125 A/G 37543395 intronic 0.150 0.37
rs5964151 G/T 37555673 3´UTR 0.149 0.45
GCLC 6 rs1014852 A/T 53478711 intronic 0.057 0.27
rs11415624 -/A 53470407 3´UTR 0.315 0.08
rs3736729 A/C 53487364 intronic 0.462 0.36
rs4140528 C/T 53469648 downstream 0.265 0.62
GCLM 1 rs7515191 A/G 94139685 intronic 0.368 0.57
rs7549683 G/T 94126037 3´UTR 0.367 0.46
GNAS 20 rs4812042 A/G 56895310 intronic 0.340 0.20
rs7121 C/T 56912202 coding (synonymous) 0.449 0.70
rs919196 C/T 56917480 intronic 0.195 0.63
GPX6 6 rs406113 A/C 28591461 coding (missense) 0.310 0.08
rs974334 C/G 28582197 intronic 0.157 0.31
GSR 8 rs1002149 G/T 30705280 promoter 0.152 0.65
rs2551715 A/G 30666178 intronic 0.375 1.00
rs2911678 A/T 30659513 intronic 0.189 0.53
rs8190996 C/T 30673548 intronic 0.437 0.81
GSS 20 rs13041792 A/G 33008716 promoter 0.202 0.63
rs2273684 G/T 32993427 intronic 0.438 0.07
rs725521 C/T 32979732 downstream 0.456 0.02
M6PR 12 rs1805754 A/C 8994515 promoter 0.236 0.16
rs933462 G/T 8994932 promoter 0.419 0.94
MSRB2 10 rs11013291 C/T 23440197 intronic 0.394 0.69
NCF2 1 rs2274064 C/T 181809010 coding (missense) 0.444 0.27
rs2274065 A/C 181826327 5´UTR 0.067 0.22
rs2296164 C/T 181801558 intronic 0.452 0.24
NCF4 22 rs2072712 C/T 35601748 coding (synonymous) 0.089 0.05
NOS1 12 rs570234 A/C 116255365 intronic 0.385 0.80
rs576881 A/G 116257218 intronic 0.372 0.62
rs816296 A/C 116255127 intronic 0.189 0.17
NOS2A 17 rs2779248 C/T 23151959 upstream 0.362 0.11
rs3729508 A/G 23133157 intronic 0.447 0.58
NOX1 X rs4827881 A/C 100016329 upstream 0.223 0.05
rs5921682 A/G 100017093 upstream 0.459 0.88
NOX3 6 rs231954 C/T 155791727 coding (synonymous) 0.442 0.02
rs3749930 G/T 155802938 coding (missense) 0.037 0.24
NOX4 11 rs490934 C/G 88863264 intronic 0.056 1.00
NOX5 15 rs2036343 A/C 67092815 promoter 0.048 0.19
rs34990910 A/G 67118435 intronic 0.027 0.38
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Table 1 Summary of the 76 selected SNPs in 27 genes (Continued)
OGG1 3 rs1052133 C/G 9773773 coding (missense) 0.213 0.87
SOD1 21 rs17881274 C/T 31953051 upstream 0.039 0.07
SOD2 6 rs2842980 A/T 160020106 downstream 0.219 0.50
rs2855116 G/T 160026115 intronic 0.454 0.12
rs8031 A/T 160020630 intronic 0.459 0.35
SOD3 4 rs2284659 G/T 24403895 promoter 0.371 0.25
TXN 9 rs2301241 C/T 112059329 promoter 0.514 0.25
rs4135168 A/G 112056706 intronic 0.222 0.82
rs4135179 A/G 112055821 intronic 0.156 0.24
rs4135225 C/T 112046512 intronic 0.390 0.29
TXN2 22 rs2281082 G/T 35202696 intronic 0.170 0.41
rs5756208 A/T 35207988 promoter 0.179 0.51
TXNRD1 12 rs10861201 A/C 103243089 intronic 0.259 0.31
rs4077561 C/T 103204498 promoter 0.387 0.46
rs4964287 C/T 103233689 coding (synonymous) 0.320 0.93
rs4964778 C/G 103210194 intronic 0.184 0.61
rs4964779 C/T 103218991 intronic 0.062 0.31
rs5018287 A/G 103231281 intronic 0.419 0.88
TXNRD2 22 rs737866 A/G 18310109 intronic 0.293 0.77
XDH 2 rs10175754 C/T 31475102 intronic 0.153 0.65
rs10187719 C/T 31453650 intronic 0.311 0.78
rs1346644 C/G 31479549 intronic 0.150 0.55
rs1429374 A/G 31425902 intronic 0.338 0.10
rs17011353 C/T 31441941 intronic 0.028 0.01
rs17011368 C/T 31444421 coding (missense) 0.044 0.54
rs17323225 C/T 31446769 coding (missense) 0.029 1.00
rs1884725 A/G 31425290 coding (synonymous) 0.234 0.20
rs206801 C/T 31482250 intronic 0.050 1.00
rs206812 A/G 31491373 promoter 0.486 0.54
rs2073316 A/G 31464533 intronic 0.427 0.69
rs207454 A/C 31421136 intronic 0.087 0.81
rs761926 C/G 31444289 intronic 0.300 0.72
Chr – chromosome; MAF – Minor Allele Frequency; HWE – Hardy Weinberg Equilibrium. amajority allele are in bold; bpolymorphisms with MAF <5% are excluded
for further analysis; cpolymorphisms with p-values <0.05 are not in HWE and they are excluded for further analysis. The information about MAF and HWE are
referent to the Set 1.
CAT: catalase; CYBB: cytochrome b-245, beta polypeptide; GCLC: glutamate-cysteine ligase, catalytic subunit; GCLM: glutamate-cysteine ligase, modifier subunit;
GNAS: GNAS complex locus; GPX6: glutathione peroxidase 6; GSR: glutathione reductase; GSS: glutathione synthetase; M6PR: mannose-6-phosphate receptor;
MSRB2: methionine sulfoxide reductase B2; NCF2: neutrophil cytosolic factor 2; NCF4: neutrophil cytosolic factor 4; NOS1: nitric oxide synthase 1; NOS2A: nitric oxide
synthase 2; NOX1: NADPH oxidase 1; NOX3: NADPH oxidase 3; NOX4: NADPH oxidase 4; NOX5: NADPH oxidase 5; OGG1: 8-oxoguanine DNA glycosylase; SOD1:
superoxide dismutase 1; SOD2: superoxide dismutase 2; SOD3: superoxide dismutase 3; TXN: thioredoxin; TXN2: thioredoxin 2; TXNRD1: thioredoxin reductase 1;
TXNRD2: thioredoxin reductase 2; XDH: xanthine dehydrogenase.
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Kit (Qiagen, Izasa, Madrid, Spain) following the
manufacturer’s protocol, but a final elution volume of
100 μl used. DNA concentration and quality were
measured in a NanoDrop spectrophotometer. Each
DNA sample was stored at −20°C until analysis, which
in all cases was performed within a year of the DNA
extraction.Genotyping analysis in both sets was performed by
SNPlex technology (Applied Biosystems, Foster City,
California, USA) according to the manufacturer’s proto-
col [21]. This genotyping system, based on oligation
assay/polymerase chain reaction and capillary electro-
phoresis, was developed for accurate genotyping, high
sample throughput, design flexibility and cost efficiency.
It has validated its precision and concordance with
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The sets of SNPlex probes were reanalyzed in about 10%
of the samples with a reproducibility of over 99%. Those
polymorphisms and samples with genotyping lower than
85% in the first set were excluded from further analysis.
Statistical and MDR analyses
Statistical analysis was performed using SNPstats soft-
ware [22], a free web-based tool, which allows the ana-
lysis of association between genetic polymorphisms and
diseases. The proper analysis of these studies can be per-
formed with general purpose statistical packages, but
this software facilitates the integration of data. The asso-
ciation with disease is modeled as binary; the application
assumes an unmatched case–control design and uncon-
ditional logistic regression models are used. The statis-
tical analyses are performed in a batch call to the R
package (http://www.R-project.org). SNPStats returns a
complete set of results for the analysis. SNPstats pro-
vides genotype frequencies, proportions, odds ratios
(OR) and 95% confidence intervals (CI), and p-values for
multiple inheritance models. The lowest Akaike’s Infor-
mation Criterion and Bayesian Information Criterion
values indicate the best inheritance genetic model for
each specific polymorphism. All the analyses were ad-
justed by age. Only SNPs with no significant deviation
from Hardy-Weinberg equilibrium (HWE) in controls
and a MAF exceeding 5% were retained for the associ-
ation analysis (Table 1).
To identify gene-gene interactions, MDR was used. It
is a non-parametric and a genetic model-free approach
that uses a data reduction strategy [23-25]. This method
considers a single variable that incorporates information
from several loci that can be divided into high risk and
low risk combinations. This new variable can be evalu-
ated for its ability to classify and predict outcome risk
status using cross validation and permutation testing.
Both were used to prevent over-fitting and false-
positives from the multiple testing. With n-fold cross-
validation, the data are divided into n equal size pieces.
An MDR model is fit using (n-1)/n of the data (the
training set) and then evaluated for its generalizability
on the remaining 1/n of the data (the testing set). The
fitness of a MDR model is assessed by estimating accur-
acy in the training set and the testing set. Moreover, it
estimates the degree to which the same best model is
discovered across n divisions of the data, referred to as
the cross-validation consistency (CVC). The best MDR
model is the one with the maximum testing accuracy.
Statistical significance is determined using permutation
testing. We used 10-fold cross-validation and 1000-fold
permutation testing. MDR results were considered statisti-
cally significant at the 0.05 level. The advantages of this
method are that there are no underlying assumptionsabout the independence or biological relevance of SNPs or
any other factor. This is important for diseases as sporadic
BC where the etiology is not completely known. We used
the MDR software (version 2.0 beta 8.4) which is freely
available (Epistasis.org: http://www.epistasis.org).
Results
Single nucleotide polymorphisms and susceptibility to
breast cancer
Set 1: To determine the possible association of poly-
morphisms related to oxidative stress genes and BC
we analyzed 76 polymorphisms in 27 genes of the redox
system in 493 cases and 683 controls (Table 1). Seven
SNPs (rs3749930, rs2036343, rs34990910, rs17881274,
rs17011353, rs17011368, rs17323225) with MAF <0.05 in
controls, as along with two SNPs (rs725521 and rs231954)
not showing Hardy-Weinberg equilibrium, were excluded
from the association analysis (Table 1). A total of 67 SNPs
were successfully genotyped and analyzed.
Our association analysis in set 1 pointed out four
nominally statistically significant results (p < 0.05).
Table 2 shows the results found in the selected polymor-
phisms. Polymorphisms rs974334, rs1805754 rs4135225
and rs207454 showed an association with modifications
in the risk for BC. All the results were adjusted by age.
Set 2: Subsequently, and in order to better identify
those polymorphisms that could be associated with BC,
we replicated the 10 SNPs with a p-value equal to or
lower than 0.15 in group 1 [rs3736729, OR: 0.74 (0.54-
1.01); rs406113, OR:1.26 (0.98-1.62); rs974334, OR:2.01
(1.07-3.80); rs1805754, OR: 1.31 (1.02-1.68); rs1052133,
OR: 1.76 (1.00-3.10); rs2284659, OR: 1.30 (0.92-1.84);
rs2301241, OR: 0.80 (0.60-1.07); rs4135179, OR: 1.27
(0.97-1.66); rs4135225, OR: 0.66 (0.45-0.96); rs207454,
OR: 4.98 (1.28-19.34)] in a second independent set.
Set 1 + Set 2: Finally, we analyzed the 10 polymor-
phisms in the global population set 1 + set 2 (n = 2409;
cases = 923, controls = 1486). The results are listed in
Table 3. From the 10 polymorphisms analyzed in both
samples, 6 presented a statistically significant association
with increased risk when the combined data were ana-
lyzed: rs406113 [OR: 1.23 (1.04-1.46)], rs974334 [OR: 1.73
(1.09-2.73)], rs1052133 [OR:1.82 (1.31-2.52)], rs2284659
[OR:1.33 (1.05-1.67), rs4135225 [OR: 0.77 (0.60-0.99)],
rs207454 [OR: 2.12 (1.11-4.04)]. Of these polymorphisms,
the rs105213 on the OGG1 gene maintained the statis-
tical significance (p-value = 0.0004) after the Bonferroni
correction.
Gene-gene interactions in breast cancer patients
There is growing evidence that epistasis interactions be-
tween genes may play a role in cancer risk, and different
variable selection approaches have been developed to
analyze the potential gene-gene and gene-environment
Table 2 Comparison of genotype frequencies between breast cancer patients and controls (Set 1)
SNP name Genetic model OR (95% CI) Genotype Controls (n = 683) Patients (n = 493) p-value* AIC
rs1049982 Recessive 0.93 (0.63-1.37) T/T 79 (12.8%) 54 (13.4%) 0.72 1309.4
C/C-C/T 537(87.2%) 350 (86.6%)
rs475043 Recessive 1.27 (0.88-1.85) G/G 75 (11.5%) 62 (13.3%) 0.21 1454.3
A/A-A/G 577 (88.5%) 404 (86.7%)
rs511895 Recessive 1.25 (0.86-1.81) A/A 74 (11.4%) 60(12.9%) 0.25 1451.9
G/G-A/G 576(88.6%) 404 (87.1%)
rs7104301 Recessive 0.78 (0.51-1.19) G/G 69 (10.6%) 40 (8.6%) 0.24 1454.3
A/A-A/G 584 (89.4%) 425 (91.4%)
rs769214 Recessive 0.86 (0.59-1.26) G/G 80 (12.5%) 57 (12.4%) 0.45 1436
A/A-A/G 560 (87.5%) 404 (87.6%)
rs5964125 Dominant 1.07 (0.81-1.40) A/G-G/G 182 (27.8%) 130 (27.8%) 0.65 1462.2
A/A 472 (72.2%) 337 (72.2%)
rs5964151 Dominan 1.10 (0.83-1.44) G/T-G/G 181 (27.7%) 133 (28.5%) 0.51 1459.3
T/T 472 (72.3%) 333 (71.5%)
rs1014852 Recessive 1.22 (0.29-5.19) T/T 4 (0.6%) 4 (0.9%) 0.79 1462.3
A/A-A/T 650 (99.4%) 463 (99.1%)
rs11415624 Recessive 0.90 (0.60-1.34) A/A 73 (11.2%) 47 (10.1%) 0.59 1458.5
D/D-D/A 579 (88.8%) 419 (89.9%)
rs3736729 Recessive 0.74 (0.54-1.01) C/C 147 (22.4%) 79 (16.9%) 0.058** 1458.7
A/A-A/C 508 (77.6%) 387 (83.1%)
rs4140528 Dominant 0.98 (0.77-1.25) C/T-T/T 297 (45.6%) 206 (44.4%) 0.87 1455.4
C/C 354 (54.4%) 258 (55.6%)
rs7515191 Recessive 1.21 (0.86-1.70) A/A 93 (14.2%) 77 (16.5%) 0.22 1461.7
G/G-A/G 562 (85.8%) 390 (83.5%)
rs7549683 Recessive 1.21 (0.86-1.70) T/T 93 (14.3%) 76 (16.3%) 0.27 1454.8
G/G-G/T 556 (85.7%) 391 (83.7%)
rs4812042 Dominant 0.96 (0.75-1.23) A/G-G/G 357 (55.6%) 258 (55.4%) 0.73 1449.3
A/A 285 (44.4%) 208 (44.6%)
rs7121 Recessive 0.97 (0.71-1.32) C/C 130 (20.3%) 93 (19.9%) 0.84 1442.5
T/T-C/T 509 (79.7%) 374 (80.1%)
rs919196 Dominant 1.12 (0.87-1.45) C/T-C/C 224 (34.3%) 169 (36.2%) 0.37 1460.2
T/T 429 (65.7%) 298 (63.8%)
rs406113 Dominant 1.26 (0.98-1.62) A/C-C/C 314 (51%) 272 (57.6%) 0.066** 1408.9
A/A 302 (49%) 200 (42.4%)
rs974334 Recessive 2.01 (1.07-3.80) G/G 18 (2.8%) 25 (5.4%) 0.03** 1452.9
C/C-C/G 633 (97.2%) 441 (94.6%)
rs1002149 Dominant 0.95 (0.72-1.26) G/T-T/T 173 (28.2%) 127 (27.4%) 0.73 1417.4
G/G 441 (71.8%) 337 (72.6%)
rs2551715 Recessive 0.88 (0.62-1.26) A/A 94 (14.4%) 60 (12.9%) 0.5 1455.5
G/G-A/G 557 (85.6%) 405 (87.1%)
rs2911678 Recessive 0.96 (0.48-1.95) T/T 20 (3.1%) 14 (3%) 0.92 1443.5
A/A-A/T 629 (96.9%) 445 (97%)
rs8190996 Recessive 1.22 (0.89-1.66) T/T 126 (19.4%) 96 (20.6%) 0.21 1456.6
C/C-C/T 524 (80.6%) 371 (79.4%)
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Table 2 Comparison of genotype frequencies between breast cancer patients and controls (Set 1) (Continued)
rs13041792 Dominant 1.13 (0.88-1.45) A/G-A/A 240 (36.9%) 181 (39.1%) 0.35 1450.9
G/G 411 (63.1%) 282 (60.9%)
rs2273684 Recessive 1.21 (0.88-1.65) G/G 115 (17.6%) 92 (19.8%) 0.24 1456
T/T-G/T 539 (82.4%) 373 (80.2%)
rs1805754 Dominant 1.31 (1.02-1.68) A/C-C/C 257 (40%) 215 (46.1%) 0.034** 1444.2
A/A 386 (60%) 251 (53.9%)
rs933462 Dominant 1.06 (0.82-1.38) G/T-G/G 431 (66.6%) 317 (68%) 0.64 1452.2
T/T 216 (33.4%) 149 (32%)
rs11013291 Recessive 1.09 (0.79-1.51) C/C 106 (16.3%) 82 (17.6%) 0.6 1458.5
T/T-C/T 546 (83.7%) 385 (82.4%)
rs2274064 Recessive 0.88 (0.65-1.20) C/C 136 (21.7%) 91 (20%) 0.42 1413.4
T/T-C/T 491 (78.3%) 364 (80%)
rs2274065 Dominant 1.21 (0.85-1.72) A/C-C/C 84 (12.9%) 69 (14.8%) 0.3 1458.9
A/A 568 (87.1%) 398 (85.2%)
rs2296164 Recessive 0.84 (0.62-1.14) T/T 143 (22.6%) 91 (19.7%) 0.25 1434.1
C/C-C/T 491 (77.4%) 370 (80.3%)
rs2072712 Dominant 1.16 (0.84-1.59) C/T-T/T 108 (16.5%) 88 (18.9%) 0.37 1461.4
C/C 547 (83.5%) 378 (81.1%)
rs570234 Dominant 1.03 (0.79-1.34) A/C-C/C 388 (63.2%) 273 (63%) 0.81 1355.7
A/A 226 (36.8%) 160 (37%)
rs576881 Dominant 1.13 (0.88-1.46) A/G-G/G 390 (60.6%) 293 (62.9%) 0.33 1448.1
A/A 254 (39.4%) 173 (37.1%)
rs816296 Dominant 1.20(0.93-1.55) A/C-A/A 211 (32.5%) 172 (36.8%) 0.17 1455.6
C/C 438 (67.5%) 295 (63.2%)
rs2779248 Recessive 0.88 (0.60-1.29) C/C 75 (11.7%) 55 (11.8%) 0.52 1444.5
T/T-C/T 569 (88.3%) 410 (88.2%)
rs3729508 Dominant 0.90 (0.69-1.18) A/G-A/A 443 (70.4%) 316 (69%) 0.46 1421.5
G/G 186 (29.6%) 142 (31%)
rs4827881 Dominant 1.00 (0.78-1.29) A/C-A/A 246 (37.6%) 177 (37.9%) 0.98 1462.8
C/C 408 (62.4%) 290 (62.1%)
rs5921682 Dominant 1.12 (0.85-1.47) A/G-G/G 459 (70.4%) 339 (72.6%) 0.42 1459.8
A/A 193 (29.6%) 128 (27.4%)
rs490934 Recessive 3.34 (0.57-19.43) C/C 2 (0.3%) 4 (0.9%) 0.16 1459.6
G/G-C/G 651 (99.7%) 463(99.1%)
rs1052133 Recessive 1.76 (1.00-3.10) G/G 34 (5.1%) 28 (8.1%) 0.051** 1124
C/C-C/G 631 (94.9%) 319 (91.9%)
rs2842980 Recessive 1.40 (0.82-2.37) T/T 31 (4.9%) 31 (6.7%) 0.22 1439.2
A/A-A/T 606 (95.1%) 435 (93.3%)
rs2855116 Dominant 0.89 (0.68-1.16) G/T-G/G 440 (69.3%) 313 (67%) 0.39 1444.1
T/T 195 (30.7%) 154 (33%)
rs8031 Dominant 0.85 (0.65-1.10) A/T-A/A 458 (70.6%) 313 (67.2%) 0.22 1454.3
T/T 191 (29.4%) 153 (32.8%)
rs2284659 Recessive 1.30 (0.92-1.84) T/T 83 (12.9%) 80 (17.2%) 0.14** 1445.6
G/G-G/T 560 (87.1%) 386 (82.8%)
rs2301241 Dominant 0.80 (0.60-1.07) C/T-C/C 460 (74.4%) 348 (71.2%) 0.14** 1350.5
T/T 158 (25.6%) 141 (28.8%)
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Table 2 Comparison of genotype frequencies between breast cancer patients and controls (Set 1) (Continued)
rs4135168 Dominant 1.17 (0.90-1.52) A/G-G/G 238 (39.9%) 183 (43.4%) 0.23 1328
A/A 359 (60.1%) 239 (56.6%)
rs4135179 Dominant 1.27 (0.97-1.66) A/G-G/G 178 (28%) 151 (32.8%) 0.085** 1431
A/A 458 (72%) 310 (67.2%)
rs4135225 Recessive 0.66 (0.45-0.96) C/C 104 (16.2%) 48 (10.5%) 0.029** 1431.1
T/T-C/T 536 (83.8%) 410 (89.5%)
rs2281082 Recessive 1.52 (0.73-3.17) T/T 15 (2.3%) 16 (3.5%) 0.26 1443.5
G/G-G/T 627 (97.7%) 447 (96.5%)
rs5756208 Recessive 1.54 (0.77-3.11) T/T 17 (2.7%) 17 (3.7%) 0.23 1438.5
A/A-A/T 618 (97.3%) 445 (96.3%)
rs10861201 Recessive 0.69 (0.41-1.17) A/A 49 (7.6%) 23 (5.1%) 0.16 1411.8
C/C-A/C 592 (92.4%) 425 (94.9%)
rs4077561 Recessive 1.20 (0.86-1.68) T/T 92 (14.6%) 80 (17.4%) 0.28 1425
C/T-T/T 540 (85.4%) 380 (82.6%)
rs4964287 Dominant 1.09 (0.85-1.40) C/T-T/T 356 (54.4%) 266 (57%) 0.48 1461.9
C/C 298 (45.6%) 201 (43%)
rs4964778 Dominant 1.17 (0.90-1.51) C/G-G/G 216 (33.1%) 171 (36.7%) 0.24 1457.3
C/C 436 (66.9%) 295 (63.3%)
rs4964779 Dominant 1.16 (0.80-1.68) C/T-C/C 76 (11.8%) 62 (13.3%) 0.43 1451.5
T/T 569 (88.2%) 405 (86.7%)
rs5018287 Recessive 1.12 (0.82-1.53) A/A 118 (18%) 91 (19.6%) 0.47 1453.9
G/G-A/G 536 (82%) 372 (80.4%)
rs737866 Dominant 1.16 (0.90-1.49) A/G-G/G 298 (49%) 234 (53.4%) 0.25 1364.1
A/A 310 (51%) 204 (46.6%)
rs10175754 Dominant 0.92 (0.69-1.22) C/T-C/C 177 (27.8%) 118 (26%) 0.55 1418.6
T/T 460 (72.2%) 335 (74%)
rs10187719 Recessive 0.80 (0.51-1.26) T/T 59 (9.9%) 34 (7.9%) 0.34 1353.8
C/C-C/T 539 (90.1%) 398 (92.1%)
rs1346644 Recessive 1.48 (0.71-3.09) G/G 16 (2.5%) 15 (3.2%) 0.29 1458
C/C-C/G 637 (97.5%) 450 (96.8%)
rs1429374 Dominant 1.15 (0.89-1.47) A/G-A/A 356 (54.9%) 274 (59%) 0.28 1450.4
G/G 292 (45.1%) 190 (41%)
rs1884725 Recessive 0.71 (0.42-1.22) A/A 42 (6.5%) 23 (5%) 0.21 1444.1
G/G-A/G 604 (93.5%) 439 (95%)
rs206801 Recessive 3.42 (0.33-35.82) T/T 1 (0.2%) 3 (0.6%) 0.27 1462
C/C-C/T 654 (99.8%) 464 (99.4%)
rs206812 Recessive 0.96 (0.72-1.28) A/A 159 (24.4%) 111 (23.8%) 0.78 1461.8
G/G-A/G 494 (75.6%) 356 (76.2%)
rs2073316 Recessive 1.14 (0.84-1.56) A/A 118 (18.6%) 95 (20.8%) 0.4 1423.7
G/G-A/G 517 (81.4%) 361 (79.2%)
rs207454 Recessive 4.98 (1.28-19.34) C/C 3 (0.5%) 9 (1.9%) 0.012** 1450.3
A/A-A/C 646 (99.5%) 457 (98.1%)
rs761926 Dominant 0.85 (0.66-1.08) C/G-G/G 334 (51.1%) 214 (45.8%) 0.18 1459.4
C/C 319 (48.9%) 253 (54.2%)
CI, confidence interval; OR, odds ratio. *p-values adjusted by age. In bold p-values <0.05. **polymorphisms with a p-value<=0.15. Set 1 (n=1176; cases=493 and
controls=683). The best model have been chosen with the criteria of lower AIC (Akaike information criterion) and lower BIC (Bayesian information criterion) values.
Only AIC is shown in table.
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Table 3 Genotype frequencies of relevant polymorphisms in different Sets
Gene SNP name Set Genetic Model OR (95% CI) Genotype Controls Patients p-value AIC
GCLC rs3736729 Set 1 Recessive 0.74 (0.54-1.01) C/C 147 (22.4%) 79 (16.9%) 0.058 1458.7
A/A-A/C 508 (77.6%) 387 (83.1%)
Set 2 Recessive 0.89 (0.67-1.19) C/C 191 (23.9%) 89 (21.8%) 0.43 1549.3
A/A-A/C 610 (76.2%) 319 (78.2%)
Set 1 + 2 Recessive 0.85 (0.73-1.00) C/C 343 (23.1%) 177 (19.7%) 0.054 3160.5
A/A-A/C 1141 (76.9%) 723 (80.3%)
GPX6 rs406113 Set 1 Dominant 1.26 (0.98-1.62) A/C-C/C 314 (51%) 272 (57.6%) 0.066 1408.9
A/A 302 (49%) 200 (42.4%)
Set 2 Dominant 1.18 (0.93-1.50) A/C-C/C 435 (54.2%) 241 (58.4%) 0.17 1559.7
A/A 367 (45.8%) 172 (41.6%)
Set 1 + 2 Dominant 1.23 (1.04-1.46) A/C-C/C 759 (52.7%) 524 (57.8%) 0.015 3127.7
A/A 681 (47.3%) 382 (42.2%)
GPX6 rs974334 Set 1 Recessive 2.01 (1.07-3.80) G/G 18 (2.8%) 25 (5.4%) 0.03 1452.9
C/C-C/G 633 (97.2%) 441 (94.6%)
Set 2 Recessive 1.45 (0.70-3.01) G/G 17 (2.1%) 13 (3%) 0.33 1592.6
C/C-C/G 785 (97.9%) 415 (97%)
Set 1 + 2 Recessive 1.73 (1.09-2.73) G/G 37 (2.5%) 39 (4.2%) 0.02 3194.7
C/C-C/G 1444 (97.5%) 881 (95.8%)
M6PR rs1805754 Set 1 Dominant 1.31 (1.02-1.68) A/C-C/C 257 (40%) 215 (46.1%) 0.034 1444.2
A/A 386 (60%) 251 (53.9%)
Set 2 Dominant 1.05 (0.83-1.34) A/C-C/C 347 (44.1%) 191 (45.4%) 0.67 1565.8
A/A 440 (55.9%) 230 (54.6%)
Set 1 + 2 Dominant 1.15 (0.98-1.36) A/C-C/C 619 (42.5%) 420 (46%) 0.093 3160.7
A/A 838 (57.5%) 493 (54%)
OGG1 rs1052133 Set 1 Recessive 1.76 (1.00-3.10) G/G 34 (5.1%) 28 (8.1%) 0.051 1124
C/C-C/G 631 (94.9%) 319 (91.9%)
Set 2 Recessive 1.84 (1.11-3.07) G/G 33 (4.1%) 30 (7.3%) 0.02 1543.7
C/C-C/G 767 (95.9%) 378 (92.7%)
Set 1 + 2 Recessive 1.82 (1.31-2.52) G/G 64 (4.5%) 56 (7.9%) 4e-04 2665.8
C/C-C/G 1348 (95.5%) 655 (92.1%)
SOD3 rs2284659 Set 1 Recessive 1.30 (0.92-1.84) T/T 83 (12.9%) 80 (17.2%) 0.14 1445.6
G/G-G/T 560 (87.1%) 386 (82.8%)
Set 2 Recessive 1.25 (0.90-1.73) T/T 109 (13.6%) 69 (16.4%) 0.19 1577
G/G-G/T 693 (86.4%) 352 (83.6%)
Set 1 + 2 Recessive 1.33 (1.05-1.67) T/T 194 (13.2%) 153 (16.8%) 0.017 3172.3
G/G-G/T 1278 (86.8%) 760 (83.2%)
TXN rs2301241 Set 1 Dominant 0.80 (0.60-1.07) C/T-C/C 460 (74.4%) 348 (71.2%) 0.14 1350.5
T/T 158 (25.6%) 141 (28.8%)
Set 2 Dominant 1.35 (1.03-1.78 C/T-C/C 569 (71.2%) 318 (77%) 0.03 1554.4
T/T 230 (28.8%) 95 (23%)
Set 1 + 2 Dominant 1.05 (0.87-1.27) C/T-C/C 1014 (72.9%) 660 (73.9%) 0.59 3060.6
T/T 377 (27.1%) 233 (26.1%)
TXN rs4135179 Set 1 Dominant 1.27 (0.97-1.66) A/G-G/G 178 (28%) 151 (32.8%) 0.085 1431
A/A 458 (72%) 310 (67.2%)
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Table 3 Genotype frequencies of relevant polymorphisms in different Sets (Continued)
Set 2 Dominant 1.08 (0.83-1.39) A/G-G/G 248 (31%) 136 (32.5%) 0.57 1571.2
A/A 553 (69%) 282 (67.5%)
Set 1 + 2 Dominant 1.14 (0.95-1.36) A/G-G/G 435 (29.7%) 294 (32.5%) 0.16 3153
A/A 1029 (70.3%) 611 (67.5%)
TXN rs4135225 Set 1 Recessive 0.66 (0.45-0.96) C/C 104 (16.2%) 48 (10.5%) 0.029 1431.1
T/T-C/T 536 (83.8%) 410 (89.5%)
Set 2 Recessive 0.97 (0.68-1.38) C/C 104 (13%) 53 (12.7%) 0.87 1574.5
T/T-C/T 698 (87%) 366 (87.3%)
Set 1 + 2 Recessive 0.77 (0.60-0.99) C/C 212 (14.4%) 104 (11.5%) 0.041 3151.7
T/T-C/T 1257 (85.6%) 799 (88.5%)
XDH rs207454 Set 1 Recessive 4.98 (1.28-19.34) C/C 3 (0.5%) 9 (1.9%) 0.012 1450.3
A/A-A/C 646 (99.5%) 457 (98.1%)
Set 2 Recessive 1.61 (0.54-4.83) C/C 7 (0.9%) 6 (1.4%) 0.4 1589.1
A/A-A/C 793 (99.1%) 421 (98.6%)
Set 1 + 2 Recessive 2.12 (1.11-4.04) C/C 11 (0.8%) 15 (1.6%) 0.024 3188.5
A/A-A/C 1464 (99.2%) 904 (98.4%)
Table polymorphisms were chosen from the analysis of the first set of patients with the criteria of a cutoff p-value equal or lower a 0.15. Bold number indicate
result statistically significant, p-value<0.05. Set 1 (n = 1176; cases = 493 and controls=683), Set 2 (n = 1233; cases=430 and controls = 803), Set 1 + set 2 (n = 2409;
cases = 923 and controls=1486). GCLC: glutamate-cysteine ligase, catalytic subunit; GPX6: glutathione peroxidase 6; M6PR: mannose-6-phosphate receptor; OGG1:
8-oxoguanine DNA glycosylase; SOD3: superoxide dismutase 3; TXN: thioredoxin; XDH: xanthine dehydrogenase.
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polymorphisms in set 1 + set 2 with susceptibility to BC
were selected for this analysis: rs406113 [OR: 1.23 (1.04-
1.46)], rs974334 [OR: 1.73 (1.09-2.73)], rs1052133 [OR:1.82
(1.31-2.52)] and rs2284659 [OR:1.33 (1.05-1.67)]. Data from
1182 samples (controls and patients) from both groups
were used. The combination was performed grouping the
genotypes according to the model predicted for the four
polymorphisms: recessive model for rs1052133 (CC and
CG were grouped into a single block), dominant model for
rs406113 (CC and AC genotypes were grouped into a single
block), recessive model for rs974334 (CC and CG geno-
types were grouped into a single block) and recessive model
for rs2284659 (GG and GT genotypes were grouped into a
single block). For a two-loci interaction, the combination of
polymorphisms rs406113 (GPX6) and rs1052133 (OGG1)
was the most significant (p = 0.041). The best three-loci
model included rs406113 on the GPX6 gene, rs1052133 on
the OGG1 gene and rs2284659 on the SOD3 gene, and it
showed statistical significance (p < 0.0007) with an OR =
1.82 and 95% CI = 1.28-2.58. A four-way interaction found
that between rs406113 on the GPX6 gene, rs974334 on the
GPX6 gene, rs1052133 on the OGG1 gene and rs2284659
on the SOD3 gene predicts breast cancer with a testing
balance accuracy of 0.5267. This four-loci model had a
chi-square value of 11.284 (p = 0.0008) and an OR of 1.75
[95% CI = 1.26-2.44]. The four polymorphism combinatory
model showed a higher predisposition to BC than the poly-
morphisms rs406113, rs974334 and rs2284659 did indi-
vidually (ORX2 = 1.23, ORX3 = 1.73, ORX6 = 1.33) and hadvalues similar to the ones of polymorphism rs1052133
(ORX5 = 1.82). The summary of the multi-factor dimension-
ality results are listed in Table 4.
The combined genotype AA for rs406113, CC/CG for
rs974334, CC/CG for rs1052133 and GG/ GT for
rs2284659 showed a higher risk for BC, which is consist-
ent with the models described for the polymorphisms in-
dividually. Figure 1 summarizes the four-loci genotype
combinations associated with high and low risk and with
the distribution of cases and controls.
Discussion
Genetic association studies involving SNPs and their
possible interactions have become increasingly import-
ant for the study of human diseases. The present study
has focused on genes encoding for proteins of the redox
system. It is long proven that they are clearly involved in
extensive damage to DNA, which in turn leads to gene
mutations and, finally, carcinogenesis. The functionality
of polymorphisms in relation to oxidative stress has been
proven in several cases. For instance, the polymorphism
in exon 2 of the superoxide dismutase 2 (SOD2) gene
A16V (C/T) (rs4880) led to structural alterations in the
domain responsible to target the mitochondria, giving a
reduction in the antioxidant potential [26]. Furthermore,
a functional polymorphism in exon 9 of the CAT gene
and other polymorphisms in endothelia NO synthase
(eNOs) that seem relevant for their activity have been
documented [26-28]. Therefore, it is clear that a single
oligonucleotide modification can lead to structural
Table 4 Summary of Multi-factor Dimensionality (MDR) results
Model Training accuracy Testing accuracy OR (95% CI) p-value CVC*
X2 0.5215 0.5093 1.18 (0.93-1.51) 0.1797 8/10
X2 – X5 0.5319 0.5199 1.30 (1.01-1.66) 0.041 8/10
X2 – X5 – X6 0.5353 0.5210 1.82 (1.28-2.58) 0.0007 7/10
X2 – X3 – X5 – X6 0.5371 0.5267 1.75 (1.26-2.44) 0.0008 10/10
The polymorphisms rs406113, rs974334, rs1052133 and rs2284659 showing the highest statistical significance in the combinatorial set1 + set 2 were chosen for
gene-gene interaction analysis. *CVC, cross-validation consistency. Testing accuracy, p-value and CVC significant were highlighted in bold.
X2 = rs406113 (GPX6), X3 = rs974334 (GPX6), X5 = rs1052133 (OGG1), X6 = rs2284659 (SOD3).
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in activity that may be relevant to the redox system. Our
hypothesis was that variations in genes from the stress
oxidative pathway, that have shown to have a possible
linkage to BC, can be associated with predisposition to
this disease. Indeed, genetic variations in these pathways
have shown to modify the risk for BC [29].
In the present epidemiological study, we have assessed
the effect of 76 SNPs in 27 genes in a case–control study in
a Spanish population. Genotype distributions in the con-
trols did not differ significantly from those expected under
HWE. The study was performed in two independent sets of
patients and controls, first, to select the relevant polymor-
phisms and second, to check the reproducibility and signifi-
cance of these preliminary results.
Six SNPs (rs406113 and rs974334 on the glutathione
peroxidase 6 (GPX6) gene, rs1052133 on the 8-oxoguanineFigure 1 The polymorphisms rs406113, rs974334, rs1052133 and rs22
combinatorial set 1 + set 2, were chosen for the gene-gene interactio
according to the genetic models selected: rs1052133 (OGG1) recessive mod
rs974334 (GPX6) recessive model; CC/CG vs. GG, rs2284659 (SOD3) recessive m
combinations associated with high and low risk. Cases: left bars, controls: right
combinations (darkest color).DNA glycosylase (OGG1) gene, rs2284659 on the super-
oxide dismutase 3 (SOD3) gene, rs4135225 on the thior-
edoxin (TXN) gene and rs207454 on the xanthine
dehydrogenase (XDH) gene) are associated with varia-
tions in the predisposition to BC.
The rs406113 (c.39 T > G; p.F13L) and rs974334
(c.242-12G > C) polymorphisms on the GPX6 gene had
not been studied previously; in fact, there was no infor-
mation available in the literature about polymorphisms
on the GPX6 gene even though they can have a func-
tional effect. Genetic variants in other genes of the GPX
family have been associated with BC [30-32].
Thioredoxin (TXN) is overexpressed in BC, and it is
related to tumor grade [33], being a crucial element in
redox homeostasis [34]. Studies of polymorphisms in the
TXN gene, encoding thioredoxin, are few in cancer. Seibold
et al. [19], evaluated the influence of common variants on84659, showing the highest statistical significance in the
n analysis. The MDR analysis was done with the genotypes collapsed
el; CC/CG vs.GG, rs406113 (GPX6) dominant model; CC/AC vs. AA,
odel; GG/GT vs. TT. The figure shows the summary of four-loci genotype
bars. The epistatic gene-gene interaction corresponds to the high risk
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2 (TXN2) genes and the risk of BC after menopause, in-
cluding seven of the SNPs analyzed in our study.
Rs2301241 and rs2281082 were not significantly related to
BC risk in our study, however, Seibold et al. found a limited
association of rs2301241 with BC risk when comparing rare
homozygote vs. common homozygote. Other studies found
a borderline significance [18]. In the case of rs2281082, the
borderline association of the Seibold study was not confirm
in other publications [19]. In our study population, we
found that carriers of one T allele on rs4135225 (c.196-
192C >T) were associated with lower risk for BC develop-
ment (OR = 0.77 [95% CI; 0.60-0.99] p = 0.041). Seidbol
et al. found a predisposition to BC for this polymorphisms
(OR = 1.22 [95% CI; 1.06-1.41]. One must take into account
that the Seidbold study is focused in postmenopausal
women, unlike ours. Still, in their analysis, they compared
only two of the three possible genotypes (heterozygotes vs.
common homozygotes). In any case, their results showed
borderline significance.
The xanthine dehydrogenase (XDH) is an important
enzyme involved in the first-pass metabolism of 6-
mercaptopurine [35]. Polymorphisms in the XDH gene
have been related to cancer. The rs1884725 polymorph-
ism has been identify as a genetic variant associated with
disease risk and outcomes in multiple myeloma [36]. In
our study, one of the thirteen polymorphisms evaluated
on this gene showed an association with BC risk. Car-
riers of one A allele of rs207454 displayed 2.12 times
([95% CI; 1.11-4.04], p = 0.024) more risk to develop the
illness than did non-carriers. To our knowledge, there
are no studies of these polymorphisms in the literature.
The results presented here suggest an association with
the development of BC, although further confirmatory
studies would be needed to confirm it.
The polymorphism on the SOD3 gene (rs2284659) an-
alyzed in our study showed a trend to the predisposition
for BC in the global analysis. There was no information
about this polymorphism in the literature. Other poly-
morphisms in this gene, like rs2536512 and rs699473,
have been associated in BC patients with the incidence
of tumor and poorer progression-free survival (PFS)
[37]. Moreover, some results suggest that rs699473 may
influence brain tumor risk [38].
The variant rs1052133 (Ser326Cys) in the OGG1 gene
has the same tendency to predisposition for BC in both
sets, separately and in the combined data set. Concerning
this polymorphism, previous studies had conflicting re-
sults [39-45]. Three meta-analyses have attempted to
summarize the results [39,41,46]. In one study, the authors
analyzed this polymorphism in relation to several cancers
founding only significant association with the risk for lung
cancer [46]. The others two meta-analyses are focused on
BC, and the results are contradictory. Yuan et al. found anassociation just in the European population subgroup [41],
while Gu et al. did not show any association, even when
stratifying the analysis by ethnicity or menopausal status
[39]. These differences may have arisen from the different
number of studies included in the European group.
We found an increment for the risk to develop BC in
the carriers of at least one Ser allele (recessive model) if
we consider the sets both separately and together ((OR =
1.82 [95% CI 1.31-2.52]) and p-value = 0.0004). Our results
are in concordance with the meta-analysis by Yuan and
collaborators that suggests that the hOGG1 326 Cys allele
provides a significant protective effect for BC in European
women [41]. The importance of this SNP rests in the role
of the 8-oxoguanine DNA glycosylase, encoded by OGG1
[47]. This enzyme can excise the 8-hydroxy-2´-deoxygua-
nosine (8-OHdG) modifications occurring in the DNA as
a result of hydroxyl radical interaction [41,48,49]. An in-
correct expression of the protein could interfere with the
suitable repair of the genetic material. Other polymor-
phisms in the OGG1 gene, like rs2304277, and recently
described by Osorio et al., have been associated with ovar-
ian cancer risk in BRCA1 mutation carriers [50]. This data
certainly support the importance of genetic changes in the
OGG1 gene in relation to the predisposition to cancer.
The epistatic analysis of the four most significant poly-
morphisms in relation to the susceptibility to BC was
performed with the MDR method. This is a reliable ap-
proach that has been widely used [23,25,51-54]. The
combination was performed grouping the genotypes ac-
cording to the model predicted for the four polymor-
phisms in Tables 2 and 3. The result obtained was an
OR = 1.75 [95% CI = 1.26-2.44; p-value = 0.0008], a value
similar to that obtained for rs1052133 (OR = 1.82 [95%
CI = 1.31-2.52; p-value = 0.0004]). The previous study of
Cebrian et al. in antioxidant defence enzymes and BC
susceptibility has twelve common SNPs with our study.
Two showed discrepancies with our data: Rs511895 in
the CAT gene was not significant in our analysis, but it
presented a borderline tendency in the Cebrian et al.
study. Moreover, they found a significant difference in
genotype distribution between cases and controls in
rs4135179 (TXN). We, however, were unable to confirm
this in our global analysis, although we detected a mar-
ginal significance in set 1. The reason for this discrep-
ancy can be found in the population’s characteristics, in
the superior age of the population included in the Ceb-
rian study [18].
Our study has several limitations to take into consider-
ation. Firstly, there is no data available about the lifestyle
of controls and patients that could be related to oxida-
tive stress, such as diet, exercise and the consumption of
tobacco and alcohol. Secondly, polymorphisms that were
not explored in our study may affect the risk to develop
BC and should be taken into account in the analysis of
Rodrigues et al. BMC Cancer 2014, 14:861 Page 13 of 15
http://www.biomedcentral.com/1471-2407/14/861our data and in further studies. Nevertheless, the associ-
ation between SNPs and risk for BC is reliable since that
power exceeded 95% in all the cases. All samples are
from the same country and ethnicity, and the adjustment
for age reduces variability.
Additionally, MDR has 80% statistical power to detect
true interactions in two-, three-, and four-way gene-gene
interactions, even with a small number of cases and con-
trols [24]. Furthermore, several associations detected in
these data involved SNPs occurring in non-coding re-
gions. However, variations in the intronic structure have
been proposed to influence cancer susceptibility via
regulation of gene expression, gene splicing or mRNA
stability. It is also possible that these polymorphisms are
in linkage disequilibrium with other functional polymor-
phisms that may affect BC susceptibility.
Despite these considerations, our work, as far as we
know, is the largest study in the Spanish population that
analyzes the influence of polymorphisms in oxidative genes
in susceptibility to BC. Overall, our data, together with that
published in the bibliography [18,19,29,37,41,45,55-62],
suggest a role of stress-response gene variants in the sus-
ceptibility to BC.
Conclusions
Our results suggest that different genotypes in genes of
the oxidant/antioxidant pathway could affect the suscepti-
bility to breast cancer. We have found six polymorphisms
in OGG1, GPX6, SOD3, TXN and XDH genes significantly
associated with predisposition to breast cancer. These as-
sociations have not been described previously, except for
rs1052133 (OGG1). Concerning this polymorphism the
published results in breast cancer were contradictory, and
some authors found only a significant association with the
risk of developing lung cancer. We have found an incre-
ment in the risk of developing breast cancer in the carriers
of at least one Ser allele (recessive model) in concordance
with a meta-analysis of breast cancer susceptibility in
European women. In this particular case, an incorrect ex-
pression of the protein encoded by the OGG1 gene could
interfere with the suitable repair of the genetic material.
Furthermore, our study highlighted the importance of the
analysis of the epistatic interactions in order to define the
influence of genetic variants in susceptibility to breast can-
cer more precisely. Further studies on the relevance of
these and other polymorphisms in the development of
breast cancer should be performed.
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